You've reached the limit for free Overall Ranking scores. For more information, request a demo.
See CSRHub in Action
You have a total of 10 free searches available.
| Low 0-29 | 30-39 | 40-49 | 50-59 | 60-79 | 80-100 High |
MultiCell is a biopharmaceutical company committed to the development and commercialization of therapeutics based on a portfolio of new drug candidates and patented drug development technology platforms. MultiCell leverages patented methods of modulating the human immune system to treat serious autoimmune diseases, including multiple sclerosis and type-1 diabetes, as well as influenza and other health threats. The Company's novel technologies include expertise in Toll-like receptors and T-cell targeting to modulate both the innate and adaptive immune systems, enabling the creation of advanced drug candidates that stimulate or suppress the immune system via disease-specific targeting of the immune system.
| Ticker: | MCET |
| ISIN: | US62544S2005 |
| Address: |
701 George Washington Highway |
| San Diego, CA, 02895, USA | |
| Website: | Multicell Technologies Inc. |
| Phone #: | (401)762-0045 |
| ESG Web Area: | Subscribers Only ? |
| Industry: | Biotechnology |
We considered many names for our site—in fact we spent our first year and a half under a different name—EkoHub. We liked “Eko” — coming from the Greek word Oikos, related to economy, ecology, and “home” or social concerns. From the beginning, we believed the word “Hub” reflected our desire to be at the center of the sustainability area, providing knowledge, harmony, and consensus among the hundreds of experts judging the ESG performance of companies.